Drug Database
TA

tafluprost + timolol maleate (Tapucom / STN 10111 / STN 1011101)

✓ Approved

Santen Pharmaceutical Co., Ltd. · ADRB1 · Small Molecule

What is tafluprost + timolol maleate?

tafluprost + timolol maleate is a small molecule developed by Santen Pharmaceutical Co., Ltd.. It is approved for therapeutic indications via others or topical.

Drug Profile

Brand NamesTapucom, STN 10111, STN 1011101
CompanySanten Pharmaceutical Co., Ltd.
Drug ClassSmall Molecule
Molecular TargetADRB1, ADRB2, PTGFR
RouteOthers, Topical
StatusApproved
Sources: ClinicalTrials.gov, Santen Pharmaceutical Co., Ltd.

Mechanism of Action

Molecular Targets

tafluprost + timolol maleate acts on 3 molecular targets:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
ADRB2adrenoceptor beta 2 (ADRBR, B2AR)
PTGFRprostaglandin F receptor (FP)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

tafluprost + timolol maleate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersGlaucoma✓ Approved

Related Research Articles

PubMedAnnales pharmaceutiques francaises2026-07-17

Design Space Exploration and Multi-Color Analytical Profiling of a BBD Assisted RP-HPLC Method for Simultaneous Estimation of Butamirate Citrate and Chlorpheniramine Maleate.

Bhaskar Siddhesh Sanjay SS, Zine Sandip Prabhakar SP, Bagul Vijay A VA, Tiwari Anand R AR et al.

Analytical Quality-by-Design principles were used to develop and validate a reverse-phase high-performance liquid chromatography method for the simultaneous quantification of butamirate citrate and chlorpheniramine maleate in pharmaceutical formulations. Box- Behnken Design systematically optimized three critical variables mobile phase pH, flow rate, and column temperature with response surface plots confirming robust chromatographic performance. Using an isocratic mobile phase of ethanol: water (40:60 v/v) containing 0.33% triethylamine and adjusted to pH 6.0 using 1% orthophosphoric acid, separation was accomplished on a Waters Spherisorb cyano column (250 mm × 4.6 mm, 5 μm) at 1.2 mL/min with photodiode array detection at 225 nm. Validation per ICH Q2(R2) demonstrated excellent linearity (r²=0.999) across 112-337 μg/mL and 10-30 μg/mL for both analytes, with percentage recoveries of 99% and 98%, respectively. Environmental sustainability was confirmed through Analytical Eco-scale (score: 80), Analytical Greenness metric (0.69), and Complex Modified Green Analytical Procedure Index (83). Analytical performance was evaluated using the Red Analytical Performance Index (70) and Multi-Color Assessment Tool (72.6%), collectively reflecting strong scope, sensitivity, accuracy, and precision. Reliable quantification of both compounds in pharmaceutical dosage forms is offered by a validated, environmentally friendly approach, supporting routine quality control and research applications.

PMID 42463072
Read full article →
PubMedAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)2026-07-17

Glaucoma prevalence and prescribing trends in New Zealand: A 10-year study.

Shi Jane J, Singh Vidit V, Nunns Brandon B, Danesh-Meyer Helen H et al.

To evaluate dispensing trends of publicly funded glaucoma medications in New Zealand from 2012 to 2021, and to assess disparities in prescribing across demographic groups. This study provides population-level insights into real-world glaucoma care and treatment equity in a universal healthcare setting. In New Zealand, although limited information exists on prescribing practices, there has been no comprehensive analysis of national dispensing data. This distinction is critical, as dispensing data more accurately reflect medication access, patient uptake, and treatment adherence than prescribing data alone. A retrospective observational study was conducted using de-identified national pharmacy dispensing data from the New Zealand Ministry of Health. Dispensing trends for eleven glaucoma medications were analysed by year, medication, sex, and self-identified ethnicity. Age-adjusted per capita dispensing rates were compared using ANOVA with post-hoc analysis. Over 3 million glaucoma prescriptions were dispensed, representing 27.6% of all ocular medications. The number of treated individuals rose from 39,725 in 2012 to 50,048 in 2021 (a 25.9% increase), outpacing national population growth. The prevalence of pharmacologically treated glaucoma or ocular hypertension increased from 0.90% in 2012 to 0.98% in 2021. The annual incidence of newly treated glaucoma was estimated at 125 per 100,000 people per year. Latanoprost was the most frequently dispensed glaucoma medication (40%), followed by timolol (13%) and bimatoprost (11%). Disparities in dispensing patterns were evident. Europeans received 87% of glaucoma prescriptions, Māori and Pasifika peoples, who represent 17.8% and 8.9% of the population, received only 1.9% and 1.4% of glaucoma prescriptions, respectively (p<0.001), even after adjusting for age. This nationwide study provides the most comprehensive analysis to date of glaucoma medication dispensing in Aotearoa New Zealand, capturing real-world treatment patterns across a ten-year period. It offers critical insight into the treated prevalence and incidence of pharmacologically treated glaucoma and ocular hypertension at a population level. Latanoprost has clearly emerged as the dominant first-line therapy, consistent with international clinical guidelines, followed by Timolol. However, the findings also expose significant inequities: Māori-the Indigenous people of New Zealand-and Pasifika populations remain markedly under-represented among those receiving glaucoma treatment, even after adjusting for age. Further research is needed to understand the underlying reasons for these disparities and to ensure equitable access to glaucoma care for all New Zealanders.

PMID 42462910
Read full article →
PubMedPediatric dermatology2026-07-16

Topical Sirolimus Therapy for Agminated Pyogenic Granulomas: A Two-Case Report.

Van Matre Stetson S, Hicks Evan E, Richter Gresham T GT, Mack Joana J

Pyogenic granulomas (PGs) are benign vascular tumors that present as rapidly growing, friable papules that often bleed and cause cosmetic disfigurement. PGs generally respond well to treatments such as excision, laser, cryotherapy, topical imiquimod, and topical timolol, but agminated PGs can be distressing to patients and challenging to treat. Topical sirolimus, an mTOR inhibitor, is used in the treatment of other vascular anomalies but has not been previously investigated for use in PGs. We report two patients with agminated PGs who demonstrated improvement in size, color, and bleeding following treatment with topical sirolimus.

PMID 42457560
Read full article →
PubMedPolymers2026-07-15

Architecture-Dependent Thermal Decomposition of RAFT-Modified Polypropylene Glycol Maleate-Acrylic Acid Copolymers: Results of TG-MS and Kinetic Analysis.

Sarsenbekova Akmaral Zh AZ, Makhmutova Almagul S AS, Zhunissova Meruyert S MS, Remetova Nazigul S NS et al.

The effect of reversible addition-fragmentation chain transfer (RAFT) polymerization on the structure, morphology, and thermal degradation behavior of polypropylene glycol maleate-acrylic acid copolymers (p-PGM:AA) was investigated using 2-cyano-2-propyl dodecyl trithiocarbonate (CPDT) as the RAFT agent. Copolymers synthesized at different CPDT concentrations were characterized by 1H/13C NMR spectroscopy, gel permeation chromatography (GPC), transmission electron microscopy (TEM), thermogravimetric analysis coupled with mass spectrometry (TG-MS), isoconversional kinetic methods, and density functional theory (DFT) calculations. 1H NMR spectroscopy revealed a progressive decrease in the relative intensity of vinyl proton signals with increasing CPDT concentration, indicating enhanced conversion of unsaturated fragments during copolymerization. Alkaline hydrolysis followed by 1H NMR and GPC analysis of the degradation products confirmed cleavage of polyester segments and yielded low-molecular-weight fragments with Mn = 1370 g mol-1 and narrow dispersity (Đ = 1.035), providing additional information on the architecture of the vinyl-polymerized segments. Increasing CPDT concentration resulted in lower molecular weights and narrower molecular weight distributions of the soluble copolymer fractions. TEM analysis demonstrated broader domain size distributions and increased morphological heterogeneity in RAFT-modified samples, accompanied by an increase in swelling degree. Thermogravimetric analysis showed that RAFT-modified systems undergo multi-stage thermal degradation with the appearance of an additional low-temperature stage associated with thermolabile fragments. TG-MS revealed earlier evolution of CO2 and oxygen-containing species and changes in the distribution of volatile products. DFT calculations indicated a decrease in the HOMO-LUMO energy gap and suggested the participation of RAFT-derived fragments in the energetic characteristics of decarboxylation processes. Isoconversional and nonlinear kinetic analyses demonstrated increased kinetic heterogeneity for branched copolymer s synthesized at elevated CPDT concentrations, whereas cross-linked systems exhibited more uniform degradation behavior. The combined experimental and theoretical results demonstrate that RAFT polymerization provides an effective route for tuning the macromolecular architecture, morphology, and thermal degradation pathways of p-PGM:AA copolymers.

PMID 42452057
Read full article →
PubMedThe Journal of dermatology2026-07-14

Topical β-Blocker as a Novel Treatment Option for Periungual Pyogenic Granuloma: A Retrospective Study of Lesion Size Reduction and Pain Improvement.

Watanabe Yoshinori Y, Ogawa-Tominaga Minako M, Katsuta Michie M, Dekio Itaru I et al.

Periungual pyogenic granuloma (PG) is a benign reactive vascular lesion commonly associated with trauma and/or drug exposure, including anticancer therapies such as epidermal growth factor receptor (EGFR) inhibitors and other targeted agents. These lesions often cause pain, bleeding, and functional impairment, and may lead to interruption or dose reduction of relevant anticancer treatment. However, there remains a need for effective and noninvasive treatment options that can be easily administered in clinical practice. This study aimed to evaluate the clinical effectiveness and safety of topical timolol in patients with periungual PG. A total of 12 patients were treated with topical timolol 0.5% applied twice daily. Clinical outcomes, including lesion size, pain visual analog scale (VAS), and Dermatology Life Quality Index (DLQI), were assessed at baseline, Week 4, and Week 8. Lesion size decreased significantly over time (p = 0.003), with a significant reduction observed at Week 8 compared with baseline (p = 0.002), corresponding to a mean reduction of 60.3% at week 8. Pain VAS significantly improved at both Week 4 (p = 0.043) and Week 8 (p < 0.001), with a mean reduction of 65.5% at Week 8 compared with baseline. DLQI also improved but did not show a statistically significant change. No significant adverse events, including significant changes in blood pressure or heart rate, were observed. In conclusion, the study suggests that topical timolol is a safe and effective treatment for periungual PG, making it a valuable supportive care strategy for patients undergoing anticancer therapy.

PMID 42444061
Read full article →
PubMedColloids and surfaces. B, Biointerfaces2026-07-08

Dual temperature-sensitive liposome-in-liposome structure for advanced drug delivery systems.

Yoo Jin J, Jo Suhyeon S, Lim Dong Wook DW, Kim Yoon Jin YJ et al.

Hierarchical liposome-in-liposome (LIL) structures enable sophisticated multi-stage drug delivery, their application is however often limited by complex, time-consuming fabrication and the use of organic solvents. Here we report a simple two-step hydration (TSH) method for fabricating stable LIL architectures in aqueous media within 2 h. This process employs ultrasonication for the formation of structurally robust inner liposomes (IL) and gentle hydration for their subsequent encapsulation within outer liposomes (OL), achieving high-quality dual-spacing configurations. Optical microscopy and differential staining verified the structural integrity and physical encapsulation, demonstrating distinct spatial segregation. The functional efficacy and temperature-sensitive release kinetics of the LIL system were validated through the release theory, confirming that the hierarchical membranes confine encapsulated agents and prevent premature leakage below the phase transition temperature (Tphase) of the OL. The programmable stepwise release was demonstrated through a macroscopic hydrogelation model, where crosslinking was triggered only upon the sequential thermal release of the initiator and accelerator. This was further validated by the independent release of commercial drugs, chlorpheniramine maleate and riboflavin sodium phosphate, as confirmed via HPLC analysis. These results validate the TSH-based LIL platform as a versatile and scalable strategy for developing smart, multi-stage delivery vehicles with environment-responsive release profiles.

PMID 42418902
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about tafluprost + timolol maleate